EGFR and neoplasm: Cetuximab is an immunoglobulin G subclass 1 (IgG1) monoclonal antibody (mAb) targeting the EGFR by preventing its ligand-mediated activation and dimerization, and it thus inhibits tumor cell proliferation and stimulates proapoptotic pathways within the tumor cell (23–25).